COVID-19 in patients with airways disease: COPD, asthma and bronchiectasis

TY - CHAP

T1 - COVID-19 in patients with airways disease

T2 - COPD, asthma and bronchiectasis

AU - Marshall, Lewis

AU - Johnson, Emma

AU - Chalmers, James D.

N1 - Publisher Copyright: © ERS 2024.

PY - 2024/9/1

Y1 - 2024/9/1

N2 - COPD, asthma and bronchiectasis patients are an increased risk of respiratory infections, and in 2020 they were assumed to be more vulnerable to COVID-19 morbidity and mortality. However, evidence suggests that these patients were not over-represented among those hospitalised during the pandemic, although considerable variability in prevalence has been observed. COPD is associated with increased mortality and more severe outcomes from COVID-19, potentially related to increased expression of ACE2, the primary receptor for SARS-CoV-2 entry into host cells. Whether asthma increases the risk of severe COVID-19 is less clear, and evidence suggests that a type 2 high endotype may offer some protection against SARS-CoV-2 infection. Currently, guidance suggests that the continuation of usual maintenance therapies, including inhaled corticosteroids and biologics, is safe in SARS-CoV-2 infection. Public health measures taken during the COVID-19 pandemic reduced the circulation of other respiratory viruses and, as a consequence, reduced the frequency of exacerbations, including hospitalisations, for people with airways diseases.

AB - COPD, asthma and bronchiectasis patients are an increased risk of respiratory infections, and in 2020 they were assumed to be more vulnerable to COVID-19 morbidity and mortality. However, evidence suggests that these patients were not over-represented among those hospitalised during the pandemic, although considerable variability in prevalence has been observed. COPD is associated with increased mortality and more severe outcomes from COVID-19, potentially related to increased expression of ACE2, the primary receptor for SARS-CoV-2 entry into host cells. Whether asthma increases the risk of severe COVID-19 is less clear, and evidence suggests that a type 2 high endotype may offer some protection against SARS-CoV-2 infection. Currently, guidance suggests that the continuation of usual maintenance therapies, including inhaled corticosteroids and biologics, is safe in SARS-CoV-2 infection. Public health measures taken during the COVID-19 pandemic reduced the circulation of other respiratory viruses and, as a consequence, reduced the frequency of exacerbations, including hospitalisations, for people with airways diseases.

U2 - 10.1183/2312508X.10005024

DO - 10.1183/2312508X.10005024

M3 - Chapter (peer-reviewed)

AN - SCOPUS:85204042978

SN - 9781849841818

VL - 2024

T3 - ERS Monograph

SP - 198

EP - 214

BT - COVID-19

A2 - Chalmers, James D.

A2 - Cilloniz, Catia

A2 - Cao, Bin

PB - European Respiratory Society

ER -